| Old Articles: <Older 3331-3340 Newer> |
|---|
 |
BusinessWeek
December 18, 2006
Keith Epstein |
The Deadly Side Effects of Net Pharmacies Operating in a legal grey area, their doctors write thousands of prescriptions for people, sight unseen. Is better regulation required?   |
The Motley Fool
December 7, 2006
Billy Fisher |
Breakout at Vanda Good news on the company's schizophrenia drug sends its shares skyrocketing. |
The Motley Fool
December 5, 2006
Brian Lawler |
Cubist Finds an Asian Partner The smaller drug developer teams up with AstraZeneca to bring its antibiotic to worldwide markets. The best part of the deal is that Cubist retains the rights to Cubicin in Japan, which is by far the biggest market in all of Asia. Investors, take note. |
The Motley Fool
December 5, 2006
Brian Lawler |
Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder. |
The Motley Fool
December 4, 2006
Michael Leibert |
Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors. |
The Motley Fool
December 4, 2006
Brian Lawler |
Success for Dynavax Solid results from the first of three phase III trials cause the biopharmaceutical Dynavax's shares to rise. |
The Motley Fool
December 4, 2006
Michael P. Cecil |
Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy? |
Pharmaceutical Executive
December 1, 2006 |
Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design. |
Pharmaceutical Executive
December 1, 2006
Rod Cavin |
Forecasting Medicare: Price Controls in the Years Ahead Part D in 2010 will be under price and access pressure. Pharma should develop plans for the future by imagining best- and worst-case scenarios. |
Pharmaceutical Executive
December 1, 2006
Richard A. Epstein |
FDA vs. the Individual In this excerpt from his important new book Overdose, an ever controversial legal scholar argues that the current system overvalues risk, ignores individual differences, and deprives patients of valuable treatments. |
| <Older 3331-3340 Newer> Return to current articles. |
